Testing effectiveness (Phase 2)Active Not RecruitingNCT04895722
What this trial is testing
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
Who this might be right for
Colorectal Cancer
Merck Sharp & Dohme LLC 302